|
Tim Williamson joined CTI's management team with our acquisition of Systems Medicine in July 2007. He is a founder of System Medicine and serves as its Chief Business Officer. Williamson's career spans 30+ years in large-cap pharma (Merck and Boehringer Mannheim), large-cap biotech (Genentech), start-up biotech (ILEX and DirectGene) and consulting. He has experience building the links and infrastructure necessary to bring innovative biotech products to market through his thorough understanding of pharmaceutical company needs and capabilities, including experience marketing new products, negotiating international product licensing agreements, building sales and marketing organizations, and building a successful start-up company from scratch (i.e., ILEX Oncology where he was one of the first three employees).
Williamson has played key roles in the development and launch of such products as Merck's first recombinant vaccine, Genentech's recombinant human growth hormone (rHGH) and recombinant tissue plasminogen activator (rTPA), and ILEX's humanized monoclonal antibody, CAMPATH. Prior to joining Systems Medicine, Williamson negotiated numerous product deals and alliances including ILEX's agreement giving Schering AG worldwide distribution rights to CAMPATH in return for $30.0 million in fees and milestones, 60% of the profit in the U.S. and a royalty comparable to 60% profit in the rest of the territory (The Pink Sheet, 08/30/99, p. 21). | 